A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
In this prospective clinical trial of daratumumab, treatment in patients with MIBC and mRCC was safe. Limited efficacy was observed. Treatment with daratumumab resulted in CD38-expressing immune cell subsets to be targeted both in circulation and within the tumor microenvironment.
Authors
- Neema Navai (ORCID: https://orcid.org/0000-0001-8457-3786)
- Colin P. Dinney (ORCID: https://orcid.org/0000-0002-8969-711X)
- Hong Chen (ORCID: https://orcid.org/0000-0003-2315-0645)
- Charles Chuanhai Guo (ORCID: https://orcid.org/0000-0003-2182-3287)
- Matthew T. Campbell (ORCID: https://orcid.org/0000-0003-1915-4491)
- Rahul A. Sheth (ORCID: https://orcid.org/0000-0001-9615-8985)
- Marc Macaluso
- Amishi Y. Shah (ORCID: https://orcid.org/0000-0002-9007-0621)
- Rebecca S. Slack Tidwell (ORCID: https://orcid.org/0000-0003-3041-8582)
- Ashish M. Kamat (ORCID: https://orcid.org/0000-0003-3546-9928)
- Aradhana M. Venkatesan (ORCID: https://orcid.org/0000-0002-5033-0820)
- Shalini S. Yadav (ORCID: https://orcid.org/0000-0001-8266-5548)
- Sonali Jindal (ORCID: https://orcid.org/0000-0002-3911-6815)
- Priya Rao (ORCID: https://orcid.org/0000-0001-5672-0961)
- Arlene O. Siefker‐Radtke (ORCID: https://orcid.org/0000-0002-6328-9599)
- Nizar M. Tannir (ORCID: https://orcid.org/0000-0001-5559-8060)
- Aidi Gu
- Fei Duan (ORCID: https://orcid.org/0000-0002-4659-0144)
- Padmanee Sharma (ORCID: https://orcid.org/0000-0003-4658-055X)
- Sreyashi Basu (ORCID: https://orcid.org/0000-0002-5028-3833)
- Pavlos Msaouel (ORCID: https://orcid.org/0000-0001-6505-8308)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0237
- Citations
- 4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- U.S. Department of Defense
- Gateway for Cancer Research
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- Exelixis
- Mirati Therapeutics
- Calithera Biosciences
- G1 Therapeutics
- Seagen
- Eisai
- Astellas Pharma
- Basilea Pharmaceutica
- EMD Serono
- University of Texas MD Anderson Cancer Center